A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC) - Lee, Yong Jae; Lee, Yoo-Young; Park, Jeong-Yeol; Cho, Hyun-Woong; Lim, Myong Cheol; Kim, Mi Kyung; Lee, Jong-Min; Lee, Jung-Yun (Journal of gynecologic oncology, 2025)
Keywords: Aged; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Brain Neoplasms; Clinical Trial Protocol; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; DNA Mismatch Repair; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - genetics; Endometrial Neoplasms - immunology; Endometrial Neoplasms - pathology; Endometrial Neoplasms - surgery; Female; Humans; Immune Checkpoint Inhibitors - administration & dosage; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Microsatellite Instability; Middle Aged; Neoplastic Syndromes, Hereditary; Nivolumab - administration & dosage; Nivolumab - adverse effects; Nivolumab - therapeutic use; Programmed Cell Death 1 Receptor - antagonists & inhibitors; 산부인과학; Endometrial Cancer; PD-L1 Inhibitor; Mismatch Repair Deficiency